---
title: "Zhejiang Dayang Biotech Group Co., Ltd. (003017.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/003017.SZ.md"
symbol: "003017.SZ"
name: "Zhejiang Dayang Biotech Group Co., Ltd."
industry: "Specialty Chemicals"
datetime: "2026-05-20T08:09:39.305Z"
locales:
  - [en](https://longbridge.com/en/quote/003017.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/003017.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/003017.SZ.md)
---

# Zhejiang Dayang Biotech Group Co., Ltd. (003017.SZ)

## Company Overview

Zhe Jiang Dayang Biotech Group Co., Ltd. operates as a chemical raw material manufacturing company in China and internationally. The company offers inorganic chemicals, including potassium carbonate and chloride, ammonium chloride, and bicarbonate food and feed additives; industrial grade potassium carbonate and bicarbonate; and agricultural and industrial grade ammonium chloride. It also provides 2-chloro-6-fluorobenzoic acid, fluorobenzaldehyde, and fluorobenzyl chloride.

| Item | Detail |
|------|--------|
| Industry | Specialty Chemicals |
| Exchange | CN Market |
| Website | [www.dyhg.com](https://www.dyhg.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.36)**

**Industry**: Specialty Chemicals

| Metric | Value |
|--------|-------|
| Industry Ranking | 46 / 154 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.46% |  |
| Net Profit YoY | 33.10% |  |
| P/B Ratio | 2.24 |  |
| Dividend Ratio | 1.91% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2623778643.19 |  |
| Revenue | 1076508938.58 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 9.02% | B |
| Profit Margin | 9.43% | B |
| Gross Margin | 23.46% | C |
| Revenue YoY | 11.46% | B |
| Net Profit YoY | 33.10% | B |
| Total Assets YoY | 13.54% | B |
| Net Assets YoY | 8.28% | B |
| Cash Flow Margin | 112.74% | C |
| OCF YoY | 11.46% | B |
| Turnover | 0.61 | B |
| Gearing Ratio | 37.61% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zhejiang Dayang Biotech Group Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "11.46%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "33.10%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.24",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.91%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2623778643.19",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1076508938.58",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "9.02%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "9.43%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "23.46%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "11.46%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "33.10%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "13.54%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "8.28%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "112.74%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "11.46%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.61",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "37.61%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 25.83 | 14/154 | 32.85 | 29.35 | 27.14 |
| PB | 2.24 | 39/154 | 2.56 | 2.41 | 2.25 |
| PS (TTM) | 2.44 | 38/154 | 2.85 | 2.68 | 2.49 |
| Dividend Yield | 1.91% | 14/154 | 1.99% | 1.84% | 0.92% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | wanhua (600309.SH) | B | B | B | D | A | B |
| 02 | Ganfeng Lithium (002460.SZ) | B | A | D | C | B | B |
| 03 | NHU (002001.SZ) | A | C | C | B | C | B |
| 04 | FEILIHUA (300395.SZ) | B | A | D | A | B | B |
| 05 | DING LONG (300054.SZ) | A | B | C | C | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/003017.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/003017.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/003017.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/003017.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**